SIDRE: Symptomatic Improvement of Dry Eye Study.

Area of Science:

• Ophthalmology
• Clinical Research
• Pharmacology

Background:

• Dry eye disease (DED) affects millions globally, impacting vision and quality of life.
• Current treatments for DED include artificial tears and anti-inflammatory agents.
• Lifitegrast is a novel small molecule drug that targets LFA-1 interactions.

Purpose of the Study:

• To evaluate the efficacy of lifitegrast 5% ophthalmic solution in alleviating DED symptoms.
• To assess changes in Ocular Surface Disease Index (OSDI) scores following lifitegrast treatment.

Main Methods:

• A single-center study involving 14 participants (12 female, 2 male) with diagnosed dry eye.
• Participants had a history of recent artificial tear use.
• OSDI scores, measuring symptom severity, visual function, and quality of life, were recorded pre- and post-treatment.

Main Results:

• The mean age of participants was 44.86 years (SD ±3.08).
• The mean OSDI score decreased from 49.40 (SD ±1.28) at baseline to 42.26 (SD ±0.99) post-therapy.
• This improvement in OSDI scores was statistically significant (p=0.00041).

Conclusions:

• Lifitegrast 5% ophthalmic solution demonstrated a significant reduction in dry eye symptoms.
• The findings suggest lifitegrast is a potentially effective therapeutic option for managing DED.
• Further research may explore long-term efficacy and safety profiles.